Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.OQ)

AVEO.OQ on NASDAQ Stock Exchange Capital Market

3.11USD
17 Nov 2017
Change (% chg)

$0.05 (+1.63%)
Prev Close
$3.06
Open
$3.07
Day's High
$3.15
Day's Low
$3.00
Volume
298,759
Avg. Vol
563,696
52-wk High
$4.24
52-wk Low
$0.50

Chart for

About

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI)... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $367.94
Shares Outstanding(Mil.): 118.31
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-AVEO PHARMACEUTICALS REPORTS Q3 LOSS PER SHARE $0.22

* AVEO REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Nov 07 2017

BRIEF-Aveo Pharmaceuticals- Tivo-3 study will continue as planned without modification

* Aveo Pharmaceuticals Inc - ‍announces completion of Tivo-3 study futility analysis with no changes to study protocol​

Oct 05 2017

BRIEF-AVEO Oncology and EUSA Pharma announce TiNivo combination study opt-in

* Aveo Pharmaceuticals Inc - ‍EUSA Pharma has agreed to pay AVEO up to $388 million in future milestone payments and research and development funding​

Sep 20 2017

BRIEF-Aveo Oncology announces Fotivda approved in the EU for the treatment of advanced renal cell carcinoma

* Aveo Oncology announces Fotivda® (tivozanib) approved in the European Union for the treatment of advanced renal cell carcinoma

Aug 28 2017

BRIEF-Aveo Pharmaceuticals Inc Q2 loss per share $0.30

* Aveo reports second quarter 2017 financial results and provides business update

Aug 09 2017

BRIEF-Aveo Oncology gets $14 mln from Hercules Credit Facility and at-the-market stock offerings

* Aveo Oncology announces $14m in aggregate gross proceeds from Hercules Credit Facility and at-the-market stock offerings

Jun 27 2017

EU regulators greenlight U.S. biotech Aveo's kidney cancer drug

European regulators on Friday recommended the approval of Aveo Pharmaceuticals Inc's drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market.

Jun 23 2017

UPDATE 1-EU regulators greenlight U.S. biotech Aveo's kidney cancer drug

June 23 European regulators on Friday recommended the approval of Aveo Pharmaceuticals Inc's drug to treat kidney cancer, marking a big victory for the U.S. biotech that has faced a number of setbacks in bringing the drug to the market.

Jun 23 2017

BRIEF-Aveo Oncology announces phase 1/2 tinivo trial

* Aveo Oncology announces phase 1/2 tinivo trial of tivozanib and opdivo® (nivolumab) in RCC advances to phase 2

Jun 08 2017

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥2,678 +15.00
Eisai Co., Ltd (4523.T) ¥6,389 +25.00
Pfizer Inc. (PFE.N) $35.37 -0.19
Novartis AG (NOVN.S) CHF83.30 +0.90
Roche Holding Ltd. (ROG.S) CHF230.10 +1.10
Roche Holding Ltd. (RO.S) CHF233.30 +1.30
Bayer AG (BAYGn.DE) €107.55 -0.35
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.43 -0.54
AstraZeneca plc (AZN.L) 4,975.00 --

Earnings vs. Estimates